{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/candida-skin/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"9ce37f9c-5801-5953-acaa-da119b97818f","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field afd7d54f-f77a-439e-9670-cbc6b582d7ef --><h2>Changes</h2><!-- end field afd7d54f-f77a-439e-9670-cbc6b582d7ef -->","summary":null,"htmlStringContent":"<!-- begin item 382e19e9-d3b1-40b7-b960-51adbf89a3e4 --><!-- begin field b4f271a8-770f-44ce-be87-a62e9a4c4af6 --><p><strong>May 2017 </strong>— reviewed. A literature search was conducted in April 2017 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials (RCTs) published since the last revision of the topic. No major changes to recommendations have been made.</p><!-- end field b4f271a8-770f-44ce-be87-a62e9a4c4af6 --><!-- end item 382e19e9-d3b1-40b7-b960-51adbf89a3e4 -->","topic":{"id":"0d4d1ca9-1f95-59a6-9163-91faf2fce35e","topicId":"44d93cc7-56e9-4f35-92ee-6fe5c97d5646","topicName":"Candida - skin","slug":"candida-skin","lastRevised":"Last revised in May 2017","chapters":[{"id":"fdd77154-68fd-5e12-ab34-4980d82ec2e8","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"20e27b79-2755-56d0-811f-79d59b1ad973","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"dc171785-2e5e-50c2-9f57-0cd56c75a2d7","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"9ce37f9c-5801-5953-acaa-da119b97818f","slug":"changes","fullItemName":"Changes"},{"id":"a9f51671-bb82-536e-9b5f-c98cb41291e6","slug":"update","fullItemName":"Update"}]},{"id":"6f439137-5e54-571e-b7aa-8cce9c5c58f6","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"7433f221-a6d1-5f98-a53d-32009abd6d65","slug":"goals","fullItemName":"Goals"},{"id":"c1df0f9d-1fa3-5aa3-96a3-7636250c141a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"1edcd62f-0185-5317-a25a-afb5e18d3d5e","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e514a54c-ae49-5bb6-9c8e-0de16f244409","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"00336847-83a8-540e-954e-23801c8eb472","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"99dacab6-3fed-5a48-ad05-74876122fa41","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"7884dd9b-ba26-56fe-8b96-29022de73f28","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"3aa00866-7e3b-5a84-9b01-091a915acd1e","slug":"definition","fullItemName":"Definition"},{"id":"82ae2b5c-db02-50a0-9572-a12b245c9f9f","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"16b02723-03c7-5877-8f98-955d9ba0adda","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"3e942288-d611-5acc-a0a5-79c5a9bbf5c3","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"815a9379-3ee5-585a-997e-8daf2e138d95","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"556293f9-6cf5-5f40-bdd2-06dfff1c5b82","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"d48752d8-0979-5908-b55c-40d0bf50e947","fullItemName":"Management","slug":"management","subChapters":[{"id":"187d27a6-4a3a-59f4-99c1-33a221ca0d2b","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"ab1b23e6-6d8b-5003-bdea-20df2a09e2b1","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"216d1aaa-ae60-548d-b753-0c53f672a4ad","slug":"topical-antifungals","fullItemName":"Topical antifungals"},{"id":"a6376d8b-e282-52b4-a990-ceb7d73afaf3","slug":"oral-fluconazole","fullItemName":"Oral fluconazole"}]},{"id":"1b822a63-5645-5cdc-9a82-7e61da577351","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"6bcfeaf8-f78c-5867-99f3-adb4fde508db","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"e9a0750e-9090-547a-aac2-eea9118c16c8","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"7624a8b0-8f03-5842-b47f-0374a546f628","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"e3980da9-5b2b-5ebb-a7ed-7edcff958155","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e3941da5-da7c-5313-b272-7df5b0bd2985","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"0839e574-758e-59d0-8520-6335161c5e49","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"3603b783-48c3-58d3-a191-1fb1ff30eca8","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"dc171785-2e5e-50c2-9f57-0cd56c75a2d7","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"440e3836-007b-5120-9125-0d509946f9f1","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field c247f2f9-d349-420d-9753-a0c5a8f8fca6 --><h3>Previous changes</h3><!-- end field c247f2f9-d349-420d-9753-a0c5a8f8fca6 -->","summary":null,"htmlStringContent":"<!-- begin item 327796a8-cbf9-4693-aae3-2fd7e9dce3e2 --><!-- begin field 775ab269-98ab-4ea1-98d2-806a5f1d9feb --><p><strong>January 2014 </strong>— minor update. Text updated to include information from the manufacturer regarding how much clotrimazole to apply to the skin.  </p><p><strong>December 2013 </strong>— minor update. Text updated to reflect that the European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) has suspended the marketing authorization for oral ketoconazole. It should no longer be prescribed for the treatment of fungal infections.</p><p><strong>August 2013 </strong>— minor update to the text to reflect recent guidance from the EMA regarding the use of oral ketoconazole  </p><p><strong>June 2013 </strong>—<strong> </strong>reviewed. A literature search was conducted in May 2013 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials (RCTs) published since the last revision of the topic. No major changes to clinical recommendations have been made. However, prescribing information nodes have been created for the topical antifungals and oral fluconazole.</p><p><strong>August 2010 </strong>—<strong> </strong>minor update. Sulconazole 1% cream (Exelderm<sup>®</sup>) has been discontinued. The prescription has been removed. Issued in August 2010.</p><p><strong>May 2009 </strong>—<strong> </strong>minor update. Econacort<sup>® </sup>cream (econazole 1% plus hydrocortisone 1% cream) has been discontinued. This prescription has been removed. Issued in June 2009.</p><p><strong>November 2008 to March 2009 </strong>—<strong> </strong>converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence.</p><p><strong>September 2008 </strong>— minor correction to the <em>Changes </em>section. Issued in September 2008.</p><p><strong>August 2008 </strong>— minor update. Nystatin cream and ointment have been discontinued. The prescriptions have been removed and text amended to reflect this. Issued August 2008.</p><p><strong>April 2008 </strong>— minor update to the text for oral ketoconazole to reflect the most recent Medicines and Healthcare products Regulatory Agency (MHRA) guidance.</p><p><strong>October to December 2005 </strong>— written. Validated in March 2006 and issued in May 2006. This is a new guidance and replaces the relevant sections that used to be in the CKS guidance on <em>Candida — skin and nails</em>. Information and recommendations have been updated following a full literature review. Oral fluconazole is now included as a treatment option for severe, extensive skin infections, or for the rare person unresponsive to topical treatment. A more detailed evidence section to support the recommendations has been included.</p><!-- end field 775ab269-98ab-4ea1-98d2-806a5f1d9feb --><!-- end item 327796a8-cbf9-4693-aae3-2fd7e9dce3e2 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}